News

PsiThera lands $25M to push AI-designed oral immunology drugs toward the clinic

What's the deal? PsiThera, a Massachusetts biotech using physics-based AI to design oral drugs for immune and inflammatory diseases, has closed a $25 million financing. Samsara BioCapitalDealroom has a profile for this one. Try Dealroom → and Lightstone VenturesDealroom has a profile for this one. Try Dealroom → led as existing investors, joined by new backers AbbVie Ventures and Lumination Capital.

What's the endgame? The company wants to turn the efficacy of injectable biologics into pills. The money funds development candidate nomination and IND-enabling studies for its lead oral TNFα inhibitor, plus advancement of its oral TL1A program into lead optimization.

Why now? This round follows a $47.5 million Series A in December 2025, and it adds AbbVie Ventures to the cap table as TL1A becomes one of the most contested targets in inflammatory bowel disease. AbbVie recently paid $150 million upfront for FutureGen's preclinical antibody, while Boehringer IngelheimDealroom has a profile for this one. Try Dealroom → and Simcere struck a separate TL1A/IL-23 deal.

PsiThera's bet is different: oral small molecules against TL1A and TNFα, rather than injectable biologics. Its QUAISAR platform combines molecular simulation, machine learning, and experimental biophysics to target transient binding pockets that conventional design misses. The company says it moved its lead TNFα program from hit identification to lead optimization in four months.

What could go wrong? The round funds early preclinical steps, not clinical proof. Its significance hinges on whether PsiThera's discovery engine can produce candidates that actually reach human testing — and TNFα, though validated, is a crowded pathway.

The signal: At $25 million, this early-stage round sits in the top 5% of US health deals at its stage by size. It reflects investor appetite for AI-native drug discovery platforms chasing oral alternatives to blockbuster biologics.

Read more: markets.financialcontent.com

Image credit: Generated with Gemini

More top stories